Rossari BiotechQ3 FY24

Rossari Biotech Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹432.9P/E: 15.7Market Cap: ₹2.4K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Company targets mid-teen (~15%) top-line growth for the next financial year, excluding CAPEX impact.
  • Export turnover expected to grow at 12%-14%, higher than domestic turnover growth forecasted around 10%.
  • HPPC division driving robust growth, with volume increases of 30%-35%+ Y-o-Y in recent quarters.
  • Institutional Chemicals, Specialty Surfactants (non-agro), and Phenoxy Series see fastest growth within HPPC.
  • New product launches and capacity expansions (notably ethoxylation at Dahej) aim to boost volumes.
  • CAPEX projects (Rs.180 crore at Dahej) expected to complete by Q3 FY25 leading to significant future sales.
  • Textile specialty division currently facing soft demand but expected to recover with domestic/export uptick.
  • Biosurfactants production targeted to expand 10x from current 3 tons/month.
  • Overall, management confident of sustained volume and revenue growth supported by R&D and capacity expansions.

See what Rossari Biotech management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
- The company is planning CAPEX investments, with a total spend of about Rs.180 crore for expansions at Dahej (Unitop and Rossari facilities). - For financing the CAPEX, the management intends to raise debt with an estimated debt-to-internal accrual ratio of approximately 75:25. - As of the call, discussions with banks regarding the debt are ongoing, and specific details on the debt quantum and interest costs are yet to be finalized. - Currently, no plans or discussions on equity fundraising or acquisitions were mentioned. - The CAPEX and related financing are expected to contribute to growth, with commissioning targeted by Q3 FY25. No explicit mention of any immediate or future equity fundraising was disclosed in the call.

See what Rossari Biotech management said on order book — free account, 30 seconds.

Capex plans

Yes
- Rossari is undertaking a total CAPEX of Rs.180 crore, primarily for the expansion of the Dahej facility and ethoxylation capacity at Unitop. - The expansion aims to foray into new products related to HPPC segments like agrochemicals, home and personal care, oil and gas, and pharmaceuticals. - CAPEX spending is phased, with significant expenditures expected in the current and next quarters and completion targeted by Q3 FY25. - An additional CAPEX of Rs.50 crore is earmarked for new equipment related to specialty textile products and pilot batches. - The company is increasing ethoxylation capacity more than twofold due to robust surfactant demand. - Plans include investment in biosurfactant capacity expansion (currently 3 tons/month, aimed to increase tenfold). - Debt-to-internal accrual ratio for financing CAPEX is expected to be roughly 75:25. - No acquisitions are currently planned in Textiles or Animal Health Nutrition segments. Overall, Rossari focuses on organic expansions across core chemistries with phased CAPEX to support growth.

Track Rossari Biotech — get its next earnings analysis in your feed

How does Rossari Biotech rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisRossari Biotech
Rev 3Mar 2

How does Rossari Biotech rank in Chemicals & Petrochemicals?

Compare Rossari Biotech against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →